{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:00:05Z","timestamp":1789617605583,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.jfo.2009.04.001","type":"journal-article","created":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T04:31:29Z","timestamp":1242621089000},"page":"309-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["H\u00e9matomes maculaires apr\u00e8s injections intravitr\u00e9ennes d\u2019anti-VEGF pour d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge\u00a0: s\u00e9rie r\u00e9trospective"],"prefix":"10.1016","volume":"32","author":[{"given":"C.","family":"Baeteman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hoffart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Galland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ridings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Conrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2009.04.001_bib1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF02697326","article-title":"Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration","volume":"39","author":"Chieh","year":"2007","journal-title":"Ann Ophthalmol (Skokie)"},{"key":"10.1016\/j.jfo.2009.04.001_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/IAE.0b013e31817e100f","article-title":"Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease","volume":"28","author":"Wong","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2009.04.001_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bjo.2007.127902","article-title":"Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration","volume":"92","author":"Goverdhan","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/00044011-200828080-00007","article-title":"Development of Vitreous Haemorrhage during Treatment with Bevacizumab for Metastatic Rectal Cancer","volume":"28","author":"Huang","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jfo.2009.04.001_bib6","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ajo.2006.07.037","article-title":"Retinal pigment epithelial tear after intravitreal bevacizumab injection","volume":"142","author":"Shah","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ajo.2006.11.047","article-title":"Retinal pigment epithelial tear after intravitreal ranibizumab","volume":"143","author":"Bakri","year":"2007","journal-title":"Am J Ophthalmol."},{"key":"10.1016\/j.jfo.2009.04.001_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/112067210701700432","article-title":"Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment","volume":"17","author":"Chan","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00417-007-0536-2","article-title":"Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration","volume":"245","author":"Lee","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/112067210601600521","article-title":"Retinal pigment epithelial tear following intravitreal injection of bevacizumab","volume":"16","author":"Nicol\u00f2","year":"2006","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/IAE.0b013e3180342c42","article-title":"RPE tears after pegaptanib treatment in age-related macular degeneration","volume":"27","author":"Chang","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2009.04.001_bib12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ajo.2005.10.053","article-title":"Retinal pigment epithelial tear following intravitreal pegaptanib sodium","volume":"141","author":"Dhalla","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/IAE.0b013e3180cc2612","article-title":"Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration","volume":"27","author":"Chan","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2009.04.001_bib14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/sj.eye.6703098","article-title":"Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration","volume":"23","author":"Gelisken","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2009.04.001_bib15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib16","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1167\/iovs.07-0731","article-title":"The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits","volume":"48","author":"Ameri","year":"2007","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"10.1016\/j.jfo.2009.04.001_bib17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1167\/iovs.07-1225","article-title":"Subretinal bevacizumab detection after intravitreous injection in rabbits","volume":"49","author":"Dib","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2009.04.001_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-2008-1027201","article-title":"Intravitreal injections during anticoagulant treatment","volume":"225","author":"Horn","year":"2008","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.jfo.2009.04.001_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2007.05.006","article-title":"Safety of intravitreal injections in patients receiving warfarin anticoagulation","volume":"144","author":"Dayani","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/PL00007887","article-title":"Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration","volume":"238","author":"Tilanus","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib21","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1136\/bjo.2006.099259","article-title":"Seasonal variations of acute massive submacular haemorrhage associated with age-related macular degeneration","volume":"90","author":"Iguchi","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/112067210501500318","article-title":"Intravitreal triamcinolone in the treatment of serous pigment epithelial detachment and occult choroidal neovascularization secondary to age-related macular degeneration","volume":"15","author":"Nicol\u00f2","year":"2005","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2009.04.001_bib23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00347-007-1655-1","article-title":"Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD","volume":"105","author":"Frimpong-Boateng","year":"2008","journal-title":"Ophthalmologe"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551209001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551209001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:00:15Z","timestamp":1759258815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551209001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0181551209001727"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2009.04.001","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"H\u00e9matomes maculaires apr\u00e8s injections intravitr\u00e9ennes d\u2019anti-VEGF pour d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge\u00a0: s\u00e9rie r\u00e9trospective","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2009.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}